Acute myeloid leukemia
Conditions
Interventions
Control group:blank
Sponsors
Shandong provincial hospital
Eligibility
Sex/Gender
All
Age
15 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. No limit in gender and the patients aged 15 to 70 years; 2. Diagnosis of acute myeloid leukemia by bone marrow examination, flow cytometry and/or cytogenetic examination; 3. Patients achieve complete remission following induction chemotherapy and undergo consolidation therapy; 4. PLT count <50x10^9/L during the previous cycle of chemotherapy; 5. ECOG performance status of <=2 at study entry; 6. With normal liver and renal function(BUN is less than or equal to 1.5 times of the benchmark value,Creatinine is less than or equal to 1.5 times of the benchmark value, SGPT/ALT is less than or equal to 1.5 times of the benchmark value,Bilirubin is less than or equal to 1.5 times of the benchmark value); 7. Patients without severe heart or lung dysfunctions; 8. No history of mental illness; 9. The estimated survival is over 12 weeks; 10. Understand and voluntarily sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with a medical history of severe allergy to biological agents; 2. Patients with a recent medical history of thrombosis; 3. Patients with thromboembolic or hemorrhagic disease; 4. Patients with M3 or M7 subtype; 5. Patients with a platelet count of >300x10^9/L at the start of consolidation therapy; 6. Pregnant or lactating patients, or patients with failure in use of contraception during the study period; 7. Other situations not approved by researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| platelet count; | — |
Secondary
| Measure | Time frame |
|---|---|
| lasting time of thrombocytopenia;quantity of platelet transfusion;Safety; | — |
Countries
China
Contacts
Public ContactWang Xin
Shandong provincial hospital
Outcome results
None listed